A Time-Resolved FRET Activity Assay to Distinguish Enzymatic Inhibition from PROTAC-Mediated Degradation of SARS-CoV-2 Mpro
Journal of Visualized Experiments · 2026
DOI: 10.3791/72318 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2026. Written by Christopher Veeck and 8 co-authors. Institution: Institute of Virology, Philipps-Universität Marburg. Major MEDLINE topics: Fluorescence Resonance Energy Transfer, SARS-CoV-2, Coronavirus 3C Proteases, Protease Inhibitors.
Abstract (original language)
Proteolysis-targeting chimeras (PROTACs) are emerging as a promising strategy for antiviral drug development and are mechanistically distinct from classical small-molecule inhibitors. Many PROTAC designs targeting viral proteases, such as the SARS-CoV-2 main protease (Mpro), employ warheads derived from active-site inhibitors, thereby combining proximity-induced degradation with potential enzymatic inhibition. This dual functionality complicates the experimental distinction between degradation-driven effects and direct inhibition of catalytic activity on viral replication. To address this, we established a fluorescence resonance energy transfer (FRET)-based assay to quantify the catalytic activity of recombinant Mpro in the presence of inhibitors and degraders. The assay employs a quenched fluorogenic peptide substrate (MI-2822) containing the canonical Mpro cleavage sequence, flanked by a fluorophore and a quencher. Proteolytic cleavage results in a time-dependent increase in fluorescence, enabling continuous kinetic monitoring of enzyme activity. Recombinant Mpro expressed in Escherichia coli is purified and incubated with the FRET substrate under defined buffer conditions, and fluorescence is recorded over time to derive enzymatic activity profiles. The assay is controlled using the clinically approved active-site inhibitor nirmatrelvir, which efficiently suppresses substrate cleavage. In contrast, PROTACs targeting Mpro outside the catalytic cleft do not substantially reduce the fluorescence increase, indicating that they do not measurably inhibit enzymatic activity under the tested conditions. This protocol provides a robust and reproducible approach to distinguish between enzymatic inhibition and degradation-associated mechanisms. It is broadly applicable for the mechanistic characterization of PROTACs and other bifunctional molecules targeting viral proteases.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Institute of Virology, Philipps-Universität Marburg.
- Institute of Pharmaceutical Chemistry, Philipps-Universität Marburg.
- Center for Tumor Biology and Immunology, Philipps-Universität Marburg.
- Institute of Virology, Philipps-Universität Marburg; Deutsches Zentrum für Infektionsforschung (DZIF), Partner Site Giessen-Marburg-Langen.
- Institute of Virology, Philipps-Universität Marburg; Deutsches Zentrum für Infektionsforschung (DZIF), Partner Site Giessen-Marburg-Langen; becker@staff.uni-marburg.de.
Cite
APA
Veeck, C., Schmacke, L. C., Jekkel, J., Laube, L., Werner, A. D., Diederich, W., Heine, A., Steinmetzer, T., & Becker, S. (2026). A Time-Resolved FRET Activity Assay to Distinguish Enzymatic Inhibition from PROTAC-Mediated Degradation of SARS-CoV-2 Mpro. Journal of Visualized Experiments. https://doi.org/10.3791/72318
Vancouver
Veeck C, Schmacke LC, Jekkel J, Laube L, Werner AD, Diederich W, et al. A Time-Resolved FRET Activity Assay to Distinguish Enzymatic Inhibition from PROTAC-Mediated Degradation of SARS-CoV-2 Mpro. Journal of Visualized Experiments. 2026. doi:10.3791/72318
BibTeX
@article{Veeck2026,
author = {Veeck, Christopher and Schmacke, Luna Clara and Jekkel, Jasmin and Laube, Lennart and Werner, Anke-Dorothee and Diederich, Wibke and Heine, Andreas and Steinmetzer, Torsten and Becker, Stephan},
title = {A Time-Resolved FRET Activity Assay to Distinguish Enzymatic Inhibition from PROTAC-Mediated Degradation of SARS-CoV-2 Mpro},
journal = {Journal of Visualized Experiments},
year = {2026},
doi = {10.3791/72318}
}
EUVIMED